Carregant...
SUN-LB024 Elevation in Morning Glucose Level May Be a Signal for the Development of Immune Checkpoint Inhibitor (ICPi) Induced Autoimmune Diabetes Insulin
Unleashing the immune system by using immune checkpoint inhibitors (ICPi) has become a powerful tool in treating a broad spectrum of malignancies. However, increasing the immune response through ICPi therapy can also induce immune-related adverse effects (irAEs). Autoimmune diabetes is a significant...
Guardat en:
| Publicat a: | J Endocr Soc |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Endocrine Society
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553107/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-LB024 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|